MSH6 and neoplasm: Although this variant is predicted to lead to an inframe deletion of five aminoacids at the protein level, we observed loss of MSH6 expression in the tumor by immunohistochemistry and detected a deleterious somatic MSH6 mutation, presumably representing the second-hit leading to biallelic inactivation.